title: Further data favouring hormonal dependency of cerebral meningiomas: evidence from a patient treated with cabergoline.
abstract: OBJECTIVE
  To explore the role of cabergoline, a dopamine agonist, in the progression of meningiomas.
  
  
  METHODS
  Case report.
  
  
  METHODS
  Teaching hospital in Barcelona, Spain (Gynecology, Obstetrics and Neonatology Clinical Institute, Hospital Clínic).
  
  
  METHODS
  Women with a history of meningioma underwent surgery via right pterional craniotomy. During the follow-up, at 18 months after the operation the patient developed a progressive hyperprolactinemia with amenorrhea and galactorrhea. An MR examination revealed a recurrence of the neoplasm.
  
  
  METHODS
  Cabergoline treatment.
  
  
  METHODS
  Progression of meningioma.
  
  
  RESULTS
  Long-standing cabergoline treatment in this patient with meningioma relapse early after surgery and subsequent hyperprolactinemia resulted in absence of progression of the neoplasm many years after the dopamine agonist initiation.
  
  
  CONCLUSIONS
  These data suggest that cabergoline, a dopamine agonist, had an antiproliferative effect on the growth of meningiomas. Thus, one can hypothesise that the proliferation of cerebral meningiomas may be under dopaminergic control and that dopamine agonists such cabergoline may have a potential role in the medical treatment of patients with meningiomas.
authors.affiliation: Institut Clinic of Gynecology, Obstetrics and Neonatology, Faculty of Medicine-University of Barcelona, Hospital Clinic-Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. castelobranco@ub.edu
authors.forename: Camil
authors.initials: C
authors.lastname: Castelo-Branco
authors.forename: María José
authors.initials: MJ
authors.lastname: Martinez
authors.forename: Juan
authors.initials: J
authors.lastname: Balasch
mesh_terms: D000328:Adult; D000077465:Cabergoline; D018450:Disease Progression; D018491:Dopamine Agonists / Q000009:adverse effects; D004873:Ergolines / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008577:Meningeal Neoplasms / Q000139:chemically induced* / Q000175:diagnosis; D008579:Meningioma / Q000139:chemically induced* / Q000175:diagnosis; D009376:Neoplasms, Hormone-Dependent / Q000139:chemically induced*
chemical_list: D018491:Dopamine Agonists; D004873:Ergolines; D000077465:Cabergoline